Admilparant NCT04308681 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Completed

Recruitment status

not reported

Planned enrollment

2022-08-04

Primary-completion proxy

Executive view

NCT04308681 evaluates Admilparant in Idiopathic Pulmonary Fibrosis. The disclosed sponsor is Bristol Myers Squibb Co., the design is Interventional, and the geographic footprint is Argentina, United States, Japan, United Kingdom, Spain, Canada, South Korea, Belgium, China, Taiwan Province, Brazil, Mexico, Italy, Israel, France, Chile, Australia, Germany. The first listed primary endpoint is Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants, assessed over From baseline (first dose) up to week 26.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT04308681 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Idiopathic Pulmonary Fibrosis landscape. Drug & Asset MCP drug_fetch was queried for Admilparant, while Company & Deal Intelligence MCP organization_fetch was queried for Bristol Myers Squibb Co..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT04308681	Admilparant	Phase 2 / Completed	Bristol Myers Squibb Co.	Argentina, United States, Japan, United Kingdom, Spain, Canada, South Korea, Belgium, China, Taiwan Province, Brazil, Mexico, Italy, Israel, France, Chile, Australia, Germany	Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants From baseline (first dose) up to week 26	2022-08-04
NCT05427253	C-106	Phase 1 / Completed	Vicore Pharma AB	Sweden	Total Number of Treatment Emergent Adverse Events (AEs) and Serious AEs (SAEs) From date of signing informed consent until End of Study, assessed up…	2023-06-22
NCT05428150	Pirfenidone	Phase 1 / Completed	Excalibur Pharmaceuticals Inc	United States	AUC 0-inf Up to Day 6 of Periods 1 and 2	2022-09-25
NCT05424887	GDC-3280	Phase 2 / Not yet recruiting	Shanghai Ark Biopharmaceutical Co., Ltd.	China	After 24 weeks of continuous medication, the absolute decrease in percentage of the predicted FVC from baseline in the… Up to 24 weeks	2024-07-01
NCT05417776	[68Ga]CBP8	Phase 2 / Recruiting	The General Hospital Corp.	United States	Degree of uptake of [68Ga]CBP8 24 months	2026-10-01

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT04308681 is a Phase 2, completed study with not reported planned participants. Allocation is Randomized, masking is Triple, and the intervention model is Parallel Assignment.

The primary endpoint is “Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants” over “From baseline (first dose) up to week 26.” The retrieved endpoint description is: Percent predicted forced vital capacity (ppFVC) is the percentage of predicted value per participant of forced vital capacity (FVC). FVC is defined as the maximum capacity of air that a participant can exhale after a maximum inspiration as measured by the volume of air exhaled in a spirometer. The data is reported as percent change from baseline in ppFVC. Percent change from baseline is a calculation that expresses the change in a value compared to its initial starting point (baseline) as a percentage, showing how much a value has increased or decreased relative to its original level; it's calculated by subtract….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Idiopathic Pulmonary Fibrosis. These records do not establish direct evidence for NCT04308681 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Admilparant is indexed as Small molecule drug with LPAR1 biology and a global stage of Phase 3. The asset profile lists Bristol Myers Squibb Co. as an originator or developer.

Bristol Myers Squibb Co. is indexed in an unreported country with the website http://www.bms.com. Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals. The record lists 303 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Admilparant is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT04308681
Protocol source: https://clinicaltrials.gov/study/NCT04308681
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 October 2026.

Admilparant in Idiopathic Pulmonary Fibrosis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Change From Baseline in Percent Predicted Forced Vital Capacity (ppFVC) in IPF Participants and 2022-08-04 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP